Antengene Corporation Limited
Status: Publicly traded
Direct answer
Antengene Corporation Limited is publicly traded on HKSE under the ticker 6996.HK.
Antengene Corporation Limited, a biopharmaceutical firm, is dedicated to developing advanced oncology treatments primarily within the Chinese market. Its active clinical development pipeline includes several innovative compounds. Among these, ATG-016, a next-generation XPO1 inhibitor, is currently undergoing Phase I/II clinical trials for individuals with solid tumors. ATG-527 (Verdinexor) has successfully completed...
Can you invest in Antengene Corporation Limited?
Yes. Antengene Corporation Limited trades publicly on HKSE as 6996.HK.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Antengene Corporation Limited
Detailed equity research is provided by MarketSnap.